Once-weekly semaglutide use in glucagon-like peptide-1 receptor agonist naïve patients with type 2 diabetes in North Macedonia: Real-world data from the MIRAGE study

Milenkovikj, Tatjana and Chekorova Mitreva, Biljana and Jovanovska Mishevska, Sasha and Bitoska-Mileva, Iskra and Ahmeti, Irfan and Velkoska Nakova, Valentina (2023) Once-weekly semaglutide use in glucagon-like peptide-1 receptor agonist naïve patients with type 2 diabetes in North Macedonia: Real-world data from the MIRAGE study. Diabetes Research and Clinical Practice, 206. p. 111018. ISSN 01688227

[thumbnail of 20. 1-s2.0-S0168822723007817-main.pdf]

Text
20. 1-s2.0-S0168822723007817-main.pdf
Download (1MB)

Official URL: https://doi.org/10.1016/j.diabres.2023.111018

Abstract

Aims: The MIRAGE study aimed to evaluate the real-world use of once weekly (OW) subcutaneous semaglutide in
glucagon-like peptide-1 receptor agonist naïve type 2 diabetes patients in routine clinical practice in North
Macedonia.
Methods: MIRAGE was a multicentre, single-arm, retrospective and 30-weeks study, conducted in North
Macedonia. Primary [change in glycated haemoglobin (HbA1c)] and secondary endpoints [change in body
weight, fasting plasma glucose (FPG), lipid parameters, blood pressure, waist circumference, glycaemic and
weight-loss target achievement] were evaluated between baseline and end of study (EOS).
Results: Baseline characteristics of 314 patients enrolled in the study were, mean age: 55.5 years, HbA1c: 9.0 %,
diabetes duration: 7.8 years, body weight: 105.2 kg and waist circumference: 114 cm. Patients at EOS experienced statistically significant estimated mean change in HbA1c: − 2.2 % points, body weight: − 9.0 kg, and FPG:
− 4.1 mmol/L (all p < 0.0001). At EOS, 62.1 % patients achieved HbA1c < 7 %, and 79.3 % had ≥ 1 % HbA1c
reduction. A weight reduction of ≥ 3 % and ≥ 5 % was noted in 88.3 % and 73.3 % patients, respectively. No new
safety concern has emerged.
Conclusions: Findings from MIRAGE study demonstrated glycaemic and weight-loss benefits of semaglutide, with
improvements in other cardiometabolic parameters. The study supports real-world OW subcutaneous semaglutide use in North Macedonia.

Item Type:	Article
Subjects:	Medical and Health Sciences > Clinical medicine
Divisions:	Faculty of Medical Science
Depositing User:	Valentina Velkovska
Date Deposited:	02 Feb 2024 12:57
Last Modified:	02 Feb 2024 12:57
URI:	https://eprints.ugd.edu.mk/id/eprint/33373

Actions (login required)

View Item